Evidence mapPaperPMID 36713994Full record

ArticleEuropean heart journal. Digital health2022

Can machine learning bring cardiovascular risk assessment to the next level? A methodological study using FOURIER trial data.

Adrien Rousset, David Dellamonica, Romuald Menuet, Armando Lira Pineda, Marc S Sabatine, Robert P Giugliano, Paul Trichelair, Mikhail Zaslavskiy, Lea Ricci

Open access · goldAbstract read
In one paragraph

Article in European heart journal. Digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Adrien RoussetAMGEN Europe GmbH, Suurstoffi 22, 6343 Rotkreuz ZG, Switzerland.
David DellamonicaAMGEN Europe GmbH, Suurstoffi 22, 6343 Rotkreuz ZG, Switzerland.
Romuald MenuetOWKIN Inc, 831 Broadway, Unit 3R NY 10003 New York City, USA.
Armando Lira PinedaAMGEN Europe GmbH, Suurstoffi 22, 6343 Rotkreuz ZG, Switzerland.
Marc S SabatineTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 350 Longwood Ave, Boston, MA 02115, USA.
Robert P GiuglianoTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 350 Longwood Ave, Boston, MA 02115, USA.
Paul TrichelairOWKIN Inc, 831 Broadway, Unit 3R NY 10003 New York City, USA.
Mikhail ZaslavskiyOWKIN Inc, 831 Broadway, Unit 3R NY 10003 New York City, USA.
Lea RicciAMGEN Europe GmbH, Suurstoffi 22, 6343 Rotkreuz ZG, Switzerland.ORCID https://orcid.org/0000-0002-0193-3676
Amgen (Switzerland) · CHBrigham and Women's Hospital · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Through this proof of concept, we studied the potential added value of machine learning (ML) methods in building cardiovascular risk scores from structured data and the conditions under which they outperform linear statistical models. Methods and results: Relying on extensive cardiovascular clinical data from FOURIER, a randomized clinical trial to test for evolocumab efficacy, we compared linear models, neural networks, random forest, and gradient boosting machines for predicting the risk of major adverse cardiovascular events. To study the relative strengths of each method, we extended the comparison to restricted subsets of the full FOURIER dataset, limiting either the number of available patients or the number of their characteristics. When using all the 428 covariates available in the dataset, ML methods significantly (c-index 0.67, Conclusion: In the field of secondary cardiovascular events prevention, given the increased availability of extensive electronic health records, ML methods could open the door to more powerful tools for patient risk stratification and treatment allocation strategies.

Indexed as

AtherosclerosisCardiovascularMachine learningMethodPreventionRisk score

Identifiers

PMID36713994
PMCPMC9707897
OpenAlexW3217680058

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.